Ginkgo Bioworks Holdings (DNA) Gains from Investment Securities (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) reported Gains from Investment Securities of $19000.0 for Q1 2026, down 88.62% on a YoY basis from $167000.0 in Q1 2025, and up 106.42% quarter-over-quarter from -$296000.0 in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Gains from Investment Securities (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings has reported Gains from Investment Securities for 7 years, with the latest figure at $19000.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities fell 88.62% year-over-year to $19000.0; the trailing twelve-month figure through Mar 2026 stood at -$277000.0 (up 93.17% YoY), and the FY2025 full-year result was -$296000.0, changed N/A from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $19000.0, up from -$296000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $97.3 million in Q4 2022, with the low at -$23.5 million in Q2 2022.
- Historically, Gains from Investment Securities has averaged $7.3 million across 5 years, with a median of $93000.0 in 2025.
- The largest YoY upside for Gains from Investment Securities was 684.78% in 2024 against a maximum downside of 172.13% in 2024.
- Ginkgo Bioworks Holdings' Gains from Investment Securities stood at $97.3 million in 2022, then sank by 100.09% to -$92000.0 in 2023, then jumped by 684.78% to $538000.0 in 2024, then tumbled by 155.02% to -$296000.0 in 2025, then surged by 106.42% to $19000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $19000.0 (Q1 2026), -$296000.0 (Q4 2025), and $167000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ginkgo Bioworks Holdings | 546.79 Mn | 546.79 Mn | 16.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19,000.00 |
| Mar 31, 2026 | 19,000.00 |
| Dec 31, 2025 | -296,000.00 |
| Dec 31, 2025 | -296,000.00 |
| Mar 31, 2025 | 167,000.00 |
| Mar 31, 2025 | 167,000.00 |
| Dec 31, 2024 | 538,000.00 |
| Dec 31, 2024 | 538,000.00 |
| Sep 30, 2024 | -1.53 Mn |
| Sep 30, 2024 | -1.53 Mn |
| Jun 30, 2024 | -3.23 Mn |
| Jun 30, 2024 | -3.23 Mn |
| Dec 31, 2023 | -92,000.00 |
| Dec 31, 2023 | -92,000.00 |
| Sep 30, 2023 | -1.89 Mn |
| Sep 30, 2023 | -1.89 Mn |
| Jun 30, 2023 | 4.48 Mn |
| Jun 30, 2023 | 4.48 Mn |
| Mar 31, 2023 | 9.38 Mn |
| Mar 31, 2023 | 9.38 Mn |